Genevieve Boland, MD, PhD
Director, Melanoma Surgery Program
Director, Surgical Oncology Research Laboratories
Surgical Director, Termeer Center for Targeted Therapies
Genevieve M. Boland, MD, PhD, FACS is an Assistant Professor at Harvard Medical School and Director of the Melanoma Surgery Program, Surgical Director of the Termeer Center for Targeted Therapies (MGH Phase I Clinical Trials Program), and Director of the Therapeutic Intralesional Program at the Massachusetts General Hospital (MGH). Her primary clinical focus is on melanoma, cutaneous oncology, and novel immuno-oncology approaches to cancer treatment.
Dr. Boland graduated cum laude from Thomas Jefferson University’s MD/PhD Program as a member of the Alpha Omega Alpha medical honor society. She completed her general surgical training at Massachusetts General Hospital. Following this, she completed a clinical fellowship in Complex General Surgical Oncology and a combined research fellowship at the University of Texas MD Anderson Cancer Center. She joined the MGH Division of Surgical Oncology and leads a translational research program in immuno-oncology. She is board certified in General Surgery and Complex General Surgical Oncology, and she is a Fellow of the American College of Surgeons.
Dr. Boland serves as the Director of the Surgical Oncology Research Laboratories and on the Executive Committee for Research (ECOR) at the MGH. She is an Associate Member of the Broad Institute of Harvard and MIT. Her research has been supported by the American Surgical Association Foundation Fellowship, the Association of Women Surgeons Research Fellowship, the Harvard Catalyst Medical Research Investigator Training Award, the Karin Grunebaum Cancer Foundation Fellowship, the Society of Surgical Oncology Clinical Investigator Award, the Melanoma Research Foundation, the, the American Cancer Society along with other industry and federal funding sources. Her laboratory is currently focused on the clinical application of immuno-oncology approaches to cancer, the molecular profiling of tumors and the tumor microenvironment, characterization of molecular and immunological changes that occur during therapy, and the identification of circulating biomarkers of cancer.